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Abstract
Autophagy is a homeostatic process that degrades long-lived or damaged proteins
and organelles. By recycling intracellular constituents, it is buffering metabolic stress
under starvation conditions. The autophagy role in cancer remains unclear and
complicated as it appears to be involved in tumorigenesis, cancer development and
treatment outcome in different ways. Autophagy can act as both tumor-promoting
and tumor-suppressing agent depending on the stage of cancer progression. During
the initiation of cancer, autophagy prevents cells from further DNA damage and
genomic instability. It could also be a cell death mechanism in cancer cells with
apoptotic defect. Autophagy can also promote tumor growth by facilitating oncogene-
induced senescence or protecting tumors against necrosis and inflammation. Once the
cancer is formed, autophagy can contribute to tumor progression (by allowing cells
to survive in stressful conditions) and metastasis. There is evidence that breast cancer
could also be controlled by autophagy. Regulation of this process, correlated proteins
and active factors are currently under scientific study in the aspect of breast cancer
effective therapeutic strategies.
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1. Introduction
Breast cancer (BC) is a potentially life-threatening malignant tumor that still causes high
mortality among women. One of the mechanisms through which cancer development could
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be controlled is autophagy. This process exerts different effects during the stages of cancer
initiation and progression due to the occurring superimposition of signaling pathways of
autophagy and carcinogenesis. Chronic inhibition of autophagy or autophagy deficiency
promotes cancer due to instability of the genome and defective cell growth as a result of cell
stress. However, increased induction of autophagy can become a mechanism which allows
tumor cells to survive the conditions of hypoxia, acidosis or chemotherapy. Therefore, in the
development of cancer, autophagy is regarded as a double-edged sword. There are different
ways of autophagy process control under scientific research for potential therapeutic treatment
in anti-cancer strategies.
2. The process of autophagy
Autophagy is a process regulated genetically and/or controlled by a group of evolutionarily
conserved genes (ATGs; autophagy-related genes). Initially, autophagy was identified as a cell
survival mechanism protecting from nutrient deprivation. It ensures homeostasis by main‐
taining proteins and organelles turnover. Removing excess or damaged intracellular compo‐
nents in response to stress as well as microorganisms allows cells to restrain damage (including
genome instability which limits initiation and progression of cancer) and subsequent inflam‐
mation. Cellular stress can be caused by a variety of chemical and physical agents like nutrient
starvation, pro-inflammatory state, hypoxia, oxidants, infectious agents and xenobiotics [1, 2].
Under the influence of autophagic pathway, biological and morphological changes have been
observed [3]. In certain developmental conditions like in cell’s response to metabolic stress or
under cytotoxic stimuli, autophagy results in a form of cell death described as programmed
cell death type II [4].
Currently, over 35 proteins are believed to be essential for autophagy occurrence and pro‐
gression [5]. The complete macroautophagy (referred to hereafter as autophagy) is generally
divided into the following stages: induction, vesicle nucleation, vesicle elongation and
completion, docking and fusion, degradation and then recycling [1, 6]. Vesicle nucleation is
the initial step in which proteins and lipids are recruited for construction of the autophago‐
somal membrane. Nucleation consists of the formation of the phagophore or isolation
membrane. In mammalian cells, this process is initiated by activation of the class III PI3K/
Beclin-1 complex including the core members hVps34/PIK3C3, Beclin-1 (BECN1) and p150.
Numerous additional binding partners of this complex function as either positive or negative
regulators and include BAX-interacting factor-1 (BIF-1), Atg14L, UVRAG (UV irradiation
resistance-associated gene), Ambra1 (activating molecule in Beclin-1-regulated autophagy
protein 1) and Rubikon [1, 5, 7-9]. Rubicon (RUN domain Beclin 1-interacting cysteine-rich-
containing protein) has also been shown to negatively regulate autophagy. Subsequently, the
phagophore is elongated by several ATG proteins. During this elongation step, microtubule-
associated protein 1 light chain 3 (LC3)-I is lapidated to LC3-II. Then, the phagophore is
maturated primarily upon the action of LC3-II and BECN1 proteins. Maturation leads to the
formation of autophagosome (enclosed vesicle). The regulation of the maturation process of
the autophagosome is multi-factorial and involves Rab GTPase, SNAREs (soluble N-ethylma‐
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leimide-sensitive fusion attachment protein receptors) and ESCRT (endosomal sorting
complexes required for transport) proteins, molecules of the acidic lysosomal compartment
(e.g. v-ATPase, LAMP proteins- lysosome-associated membrane glycoprteins; lysosomal
carriers and hydrolases) and Beclin-1. Finally, the autophagosome fuses with the lysosome to
form an autolysosome. The internal material of the autophagic vacuole is degraded by the
lysosomal hydrolases.
Basal levels of macroautophagy are kept in check by mTORC1 (mammalian target of rapa‐
mycin complex 1) which phosphorylates Atg13 and ULK1 (uncoordinated 51-like kinase 1/
Atg1) or ULK2. This activity in consequence is giving the inhibition of FIP200 (focal adhesion
kinase interacting protein of 200 kD/Atg17) phosphorylation by ULK1 [10]. The mTORC1
complex is an important component of a network that accordingly maintains homeostasis by
controlling the levels of anabolism and catabolism. For example, high levels of amino acids
maintain mTORC1 in an active state by enhancing its binding to regulatory GTPases, Rag (Ras-
related GTPase) and Rheb (Ras homolog enriched in brain) [11]. mTORC1 activity could be
indirectly induced by insulin and IGF1 (insulin like growth factor 1) [6]. Low glucose levels or
high AMP levels (adenosine 5’-monophosphate), indicators of low cellular energy status or
stress, could activate AMPK (AMP-activated protein kinase) which in turn inhibits mTORC1
and stimulates autophagy [2,7].
The role of the PI3K/Akt pathway is to suppress autophagy. This pathway activation was
shown to decrease autophagy through mTOR activation. It has been considered for cancer
treatment. The MAPK pathway also plays a significant role in autophagy. Ras may play a dual
role in autophagy [12]. When Ras activates PI3KCA, autophagy is inhibited; however, when
it selectively activates the MAPK pathway, autophagy is stimulated.
3. Breast cancer
Breast cancer (BC) is the most common and fatal cancer in women worldwide. Decreasing
mortality rates can be observed that result mostly from efficient screening strategies [13] but
still BC is ranked on the second place in mortality among cancer types [14]. It has been
estimated that approximately 1.3 million females develop BC each year with around 465.000
expected to succumb to the disease [15,16]. It is causing death of about 350.000 women in both
developed and developing countries every year (with slightly more cases in less developed
than in more developed regions) [17]. According to another data presented by DeSantis et al.,
there are still 500.000 breast cancer deaths per year worldwide [18]. More than 90% of lethality
in patients is caused by metastasis and the occurrence of distant metastases (distinct metastatic
pattern involving the regional lymph nodes, bone marrow, lung and liver) severely limits the
prognosis [19,20]. The 5-year survival rate for patients with BC drops sharply from 98% for
individuals with localized disease to 23% for those with metastatic disease (cancer statistics
from 2012) [21]. A significant subpopulation of patients with metastasis risk has a median
survival time of 18–30 months [22].
Targeting the Autophagy Process in Breast Cancer Development and Treatment
http://dx.doi.org/10.5772/61181
65
In the pathogenesis and progression of BC are involved many factors including genetic,
biological and environmental factors as well as a lifestyle [17]. For example, Bcl-2 protoonco‐
gene is overexpressed in half of all human malignancies and more than 60% of BC and exerts
its oncogenic role by preventing cells from undergoing apoptosis [23]. Still, the disease
background is not fully clear because it has been estimated that 75% of women with sporadic
invasive BC have no known epidemiological risk factors [24].
4. Autophagy regulation in breast tumors development
In tumor genesis and treatment responsiveness, autophagy role is complicated and context-
dependent. It presumably differs in different stages of cancer development. At the initial
stages, autophagy may represent a protective role thanks to its catabolic functions by degrad‐
ing and/or recycling cell components (e.g. damaged organelles and misfolded proteins) [25-27].
It also protects against the deleterious effects of ROS (reactive oxygen species) in the cells.
Proliferation of cells with cancer-linked mutations may be retarded by autophagy. It can also
limit propagation of this type of mutations and consequently suppress tumorigenesis by
facilitating the cellular senescence phenomenon (biological aging). However, once a tumor
develops, the cancer cells can utilize autophagy for their own cytoprotection and use enhanced
autophagy to survive under metabolic and therapeutic stress [27]. Autophagy might increase
oxidative stress, hence promoting genome instability and malignant transformation [25-27].
As an example, autophagy has been shown to be required for the transformation of mouse
embryonic fibroblasts by the Ras oncogene and this effect is linked to its role in nutrients
recycling, such as glucose uptake and increased glycolytic flux [28]. What's more, it has been
suggested that metastatic cancer cells can escape from anoikis (process of apoptosis induced
by lack of correct cell-ECM attachment) through the autophagy induction [29, 30]. The AMP-
activated protein kinase (AMPK) stress response pathway is involved in mediating anoikis
resistance by inhibiting mTOR and suppression of protein synthesis. The Ras/MAPK and PI3K/
Akt pathways are common mechanisms utilized by cancer cells to evade anoikis. Autophagy
is necessary for cancer cells survival in hypoxic conditions during the later stages of in vivo
tumor formation before the vascularization of tumor takes place [31, 32]. However, the
induction of autophagy is associated with cell death in normal cells and in some cancer cells
[23]. Autophagic cell death has been described e.g. in anti-estrogen-treated cultured human
mammary carcinoma MCF-7 cells [33].Some studies have shown that cancer cells express lower
levels of the autophagy-related proteins LC3-II and Beclin-1 than normal epithelial cells. There
is evidence that heterozygous disruption of BECN1 promotes tumorigenesis and the overex‐
pression inhibits tumorigenesis, which support the assertion, that defective autophagy or
inhibition of autophagy playing a role in malignant transformation [23].
The ability of cancer cells to invade and metastasize is closely correlated with the process of
epithelial-mesenchymal transition (EMT). It was recently demonstrated that ectopic expres‐
sion of the DEDD gene in the MDA-MB-231 metastatic BC cell line led to the degradation of
the EMT inducers Snail and Twist through autophagy activation [34]. Reversely, knock-down
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of DEDD in the MCF7 non-metastatic BC cell line led to autophagy reduction and EMT
promotion [34].
Regulation of autophagy in tumors is governed by principles similar to normal cells only in a
much more complicated manner. Abnormal PI3K activation in cancer cells is frequently
observed. The multitude of interactions between the PI3K/Akt/mTOR pathway and other cell
signaling cascades could often be deregulated [7]. For example, Ras ⁄Raf ⁄ERK pathway,
indicated as one of the most commonly deregulated pathways identified in tumors, frequently
are observed activating mutations in Ras or B-Raf oncogenes [4]. ERK activity has been
associated with autophagy and autophagic cell death in many cellular models in response to
different stresses [4]. It also happens in TNFalpha treatment in MCF-7 cells. A deregulated
PI3K/Akt/mTOR axis not only suppresses autophagy process but also induces protein
translation, cell growth and proliferation thereby can force tumorigenesis. Tumors with
constitutively active PI3K mutations, PTEN loss or Akt activation would be expected to be
dependent on autophagy for energy homeostasis and survival. Suppression of autophagy by
the PI3K cascade is disadvantageous for rapidly proliferating tumor cells and there are theses
that compensatory mechanisms (like deregulated apoptosis and/or metabolism) might be
concurrently activated to prevent the negative implications of defective autophagy on tumor
cell survival.
Many proteins and active factors correlated with autophagy are reported to be associated with
human cancers [35]. Various tumor suppressors (e.g. PTEN, TSC1/2, p53, and DAPK) are
autophagy inducers whereas some inhibitors of autophagy (e.g. Akt and Ras) possess onco‐
genic activity [36]. Some studies [37, 38] showed that the more advanced stages of breast cancer
over-express several other oncogenic and signaling proteins such as IGF-1R, Cyclin D1, c myc,
pERK, Stat3 and Pak4. Some are known activators of Akt/mTOR pathway. Several other
autophagy regulators like mitogen-activated kinases (BNIP3) [39] and HSpin 1 (human
homologue of the Drosophila spin gene product) [40] play a critical role in cancer cells. Deletion
of the essential autophagy gene FIP200 impairs oncogene-induced tumorigenesis in a mouse
model of breast cancer [41].
PTEN, a critical regulator of the PI3K pathway, has a stimulatory effect on autophagy by
downregulating PI3K/Akt signaling through inhibition of the Akt/PKB activation. Akt
inhibition leads to mTOR signaling suppression and the induction of autophagy [42]. AMPK
(AMP-activated protein kinase) pathway has a negative effect on mTOR signaling and
promotes autophagy (e.g. upon starvation conditions by activation of Tuberin -TSC2 and/or
mTOR signaling inhibitor).
EI24/PIG8 (etopside induced gene) can be mentioned as another critical factor of autophagic
degradation. It remains under control of p53 [43, 44] - well known critical tumor suppressor.
p53 effects protectively by cell cycle arrest initiation, removal of cells with incurred DNA
damage, senescence and apoptosis. The human EI24 genomic locus is on chromosome 11 in
region frequently altered in cancers and was reported to be mutated in aggressive breast
cancers. Furthermore, since EI24/ PIG8 (induced by p53) is also known as important apoptotic
effector [43, 45], its role may contribute to tumor suppression. EI24/PIG8 loss was associated
with tumor invasiveness but not with the development of the primary tumor [45].
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mTORC1, class I PI3K, Akt, class III PI3K, Beclin-1 and p53 are critical components of the
autophagic pathway that have become major targets of autophagy-related drug design. As an
example, rapamycin and its derivatives (e.g. rottlerin, PP242 and AZD8055) target the
PI3K/Akt/mTOR signaling pathway to induce autophagy. Spautin-1 and tamoxifen regulate
Beclin-1 activity to respectively inhibit and promote autophagy. Oridonin and metformin
trigger p53-mediated autophagy and cell death [46].
4.1. Beclin-1 role
The most important evidence linking dysfunctional autophagy and cancer come from studies
on mice demonstrating that the inhibition of autophagy by disruption of BECN1 increases
cellular proliferation, the frequency of spontaneous malignancies (i.e. lung cancer, liver cancer
and lymphomas) as well as mammary hyperplasia. It also accelerates the development of
carcinogen-induced premalignant lesions [23]. Additionally, low levels of Beclin1 in human
MCF-7 BC cell line can inhibit tumor cell growth [47].
Human breast cancer cell lines FISH analysis with the Beclin-1-containing PAC 452O8 as a
probe revealed that 9 out of 22 cell lines had allelic BECN1 deletions [7]. Monoallelic deletion
of BECN1 has been also detected in 40-75% cases of human breast, ovarian and prostate tumors
[2, 26]. Thereby BECN1 is considered as a tumor suppressor gene [48]. Deletions of Beclin-1
have recently been found mostly associated with BRCA1 in breast and ovarian human tumors
(suggesting that BRCA1 loss is the mutation driver and that Beclin-1 is lost because of its
proximity to it) [49]. Many breast carcinoma cell lines, although polyploidal for chromosome
17 (BECN1 gene is placed in 17q21 loci), exhibit deletions of one or more BECN1 alleles. The
aberrant expression of Beclin-1 in many kinds of tumors correlates with poor prognosis [26].
Also, heterozygous deletion of BECN1 in mice (BECN1+/−) resulted in increased incidence of
spontaneous tumors [48]. Those mice do not have increased incidence of mammary tumors
but rather are susceptible to lymphomas and lung carcinomas. BECN1+/− mice tumors express
wild-type BECN1 mRNA and protein indicating that Beclin-1 is a haploinsufficient tumor
suppressor [7, 8]. The Beclin-1 loss occurring in BC could have important effects independent
of autophagy through its interaction with Bcl-2. Bcl-2 is overexpressed in 50%-70% of cancers
including BC. An inverse correlation of Beclin-1 and Bcl-2 expression has been described in
breast cancer tissue. Bcl-2 expression was correlated with histological grade, tubule formation,
nuclear pleomorphism, mitotic count, ER and distant metastasis [49].
Beclin-1 also alters the expression of several autophagy proteins such as Atg5 and UVRAG [26].
4.2. Adipokines role
Adipokines, auto-/ endocrine and paracrine-acting bioactive molecules secreted by adipose
tissue are one of the recently discovered factors correlating with autophagy and BC [50].
Adiponectin (AdipoQ) is the cytokine secreted in greatest abundance. The prevalence correlate
low levels of AdipoQ in the blood circulation with higher BC risk and poorer prognosis. In
breast tissue, AdipoQ has a direct anti-carcinogenic effect at the site of tumor growth. This
cytokine is potentially capable of regulation of autophagy through AMP kinase (5'AMP-
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activated protein kinase) and its activation has been observed in breast cancer cells [50]. Liu
and colleagues observed that AdipoQ caused upregulatation of autophagy in MDA-MB-231
cells in vitro and in vivo in cholesterol induced mammary tumorigenesis [51].
4.3. microRNA role
MicroRNAs (miRNAs) are endogenous ~22 nucleotide RNAs that suppress gene expres‐
sion via  messenger  RNA (mRNA) cleavage and/or  translational  repression.  Unregulated
miRNAs of lymphoma, prostate, lung and breast cancers have been also detected in blood
plasma and serum. Circulating miRNAs are currently assessed as proxy biomarkers for BC
[52]. There is evidence that miRNAs can influence autophagy process in BC cells at many
points. MiR-20a, miR-101, miR-106a/b and miR-885-3p have been reported to have direct
possibility of targeting ULK1/2 [53]. Also, miR-155 might target multiple players in mTOR
signaling  including  Rheb,  RICTOR  (RPTOR  independent  companion  of  mTOR)  and
RPS6KB2  (ribosomal  protein  S6  kinase).  MiR-30a  and  miR-519a  can  directly  target  Be‐
clin-1 causing negative regulation in the autophagic flow thereby resulting in decreased
autophagic activity. Action of miR-30a was shown in the in vitro study on human BC cell
lines MDA-MB-468 and MCF-7 [54] by Zhu et al. Tumor cells treatment with the mimic of
miR-30a decreased the expression of Beclin-1 mRNA and protein whereas administration
of the miR-30a antagomir had opposite effects. Furthermore, high expression of miR-30a
blunted the rapamycin-induced autophagy activation [54]. Another miRNA, miR-376b also
regulates  Beclin-1  and  it  is  also  targeting  directly  Atg4C  [9,  55]  in  MCF-7  cells.  The
antagomir-mediated inactivation of the endogenous miR-376b results in an increased level
of Atg4C and Beclin-1 [56]. MiR-374a and miR-630 can modulate the direct regulation of
UVRAG. The tumor suppressive miR-101 could act as a potent inhibitor of basal, etoposide-
induced and rapamycin-induced autophagy in  MCF-7 cells.  Also,  the  miR-101-mediated
inhibition of autophagy sensitized BC cells to 4-hydroxytamoxifen-induced apoptotic cell
death and thus miR-101 was suggested to modulate the chemosensitivity of cancer cells [9].
Elevated levels of autophagy due to the progressive loss of miR-101, at least in breast cancer
cells,  have the potential  to trigger cancer cell  survival [9,  57].  Three components includ‐
ing STMN1 (stathmin1), RAB5A (ras related protein 5A) and Atg4D have been identified
as targets of miR-101 among which the over-expression of STMN1 could partially rescue
cells  from miR-101-mediated  inhibition  of  autophagy.  Previously  described RAB5A and
STMN1 had uncertain roles in autophagy.  RAB5A have been shown to regulate ATG5–
ATG12 conjugation in the autophagosome completion while STMN1 plays an important
role in cell-cycle regulation [58]. Another miRNA, miR-221/222, might inhibit the cell cycle
inhibitor,  p27Kip1,  a  downstream modulator  of  PI3K/Akt thereby leading to autophagic
cell death in HER2/neu-positive primary human breast carcinoma MCF-7 cells. The ectopic
expression of miR-221/222 renders the parental MCF-7 cells resistant to tamoxifen [59].
4.4. Cancer Stem Cells (CSC) and autophagy
Autophagy is thought to be a critical process for cancer stem cells (CSC) or tumor initiating
cell maintenance but the mechanisms through which autophagy supports survival of CSCs
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remain poorly understood [60]. The CSC theory proposes that heterogeneity within a tumor
is driven by a small population of cells which have ability to differentiate and/or self-renewal,
increased membrane transporter activity, anchorage independence and ability to migrate,
tumorigenic capacities and pluripotency [61, 62]. Breast cancer follows this model since it has
been shown that the CD44+/ CD24 low/-phenotype of cell surface markers (which can be found
also in normal stem cells in the breast), have an increased ability to form tumors in immuno‐
suppressed mice than the bulk of the tumor cells. It has been predicted that a quality control
mechanism like autophagy is important for maintaining normal and cancer stem cell homeo‐
stasis [63]. Maycotte et al. have previously reported that a subset of BC cell lines enriched in
the triple negative (TN) type is particularly dependent on autophagy for survival even in
nutrient rich conditions [49]. This process is regulated by autophagy through modulation of
STAT3 activity (often activated in TNBC). STAT3 activity is known to be regulated by IL-6
(interleukin 6) paracrine signaling in breast cancer cell lines [64]. The IL-6/ STAT3 pathway
has been also shown to be important for TNBC xenograft growth and breast CSC maintenance
[65]. Maycotte et al. have found that the pathways most affected by autophagy inhibition were
related to stem cells, secretion and epithelial to mesenchymal transition [49]. We also show
that autophagy regulates the CD44+/CD24 low/-phenotype and mammosphere formation in
both the MCF7 and MDA-MB-468 breast cancer cell lines. Although autophagy regulates IL-6
secretion in both the autophagy dependent (MDA-MB-468) and independent (MCF7) cell lines,
autophagy inhibition increased IL6 secretion in MCF7 cells while it decreased it in MDA-
MB-468 cells. Decreased mammosphere formation in MDA-MB-468 cells induced by autoph‐
agy inhibition was reversed with conditioned media from autophagy proficient MDA-MB-468
cells or with IL-6 treatment. This identifies a mechanism by which autophagy selectively
regulates CSC maintenance in autophagy-dependent breast cancer cells. Maycotte et al. had
used a flow cytometry based assay to analyze CD24 and CD44 staining in cells with different
levels of autophagic flux (“autophagic flux” represents the synthesis of autophagosomes,
transportation of different substrates and degradation of autophagy inside the lysosome) [49].
In both MCF7 and MDA-MB-468 cell lines, the cells with low autophagic flux had decreased
CD24 staining. Cells expressing a shRNA for ATG7 or BECN1 had lower levels of CD24
staining in both cell lines and no changes in CD44 were observed indicating that cells with
lower levels of autophagy also have lower levels of CD24 expression.
CSCs are characteristically resistant to conventional anticancer therapy which may contribute
to treatment failure and tumor relapse. CSCs exhibit the potential for regeneration which may
promote tumor metastasis [66]. Recently, autophagy has been shown to be a critical factor for
CSC survival and drug resistance [67].
5. Authophagy in anti-breast cancer therapies
There are different ways of autophagy process usage and/or influence recognized according
to potential therapeutic treatment in anti-cancer strategies.
Inducing protective autophagy and prosurvival mechanism in human cancer cell lines have
been shown in a number of currently used antineoplastic therapies including radiation
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therapy, chemotherapy (e.g. doxorubicin, temozolomide and/or etoposide), histone deacelty‐
lase inhibitors, arsenic trioxide, TNFα, IFNγ, imatinib, rapamycin and anti-estrogen hormonal
therapy (e.g. tamoxifen) [12, 23]. In fact, the therapeutic efficacy of these agents can be increased
if autophagy is inhibited [23].
The scientific evidence suggests that autophagy leads to cell death in response to several
compounds including etoposide, rottlerin, cytosine arabinoside and staurosporine as well as
deprivation of growth-factors. A link has been demonstrated between autophagy and related
autophagic cell death with usage of pharmacological inhibitors (e.g. 3-MA (3-methyl adenine),
CQ (chloroquine), bafilomycin A1 or ammonium chloride) and genetic silencing or knock‐
down (silencing of BECN1 and ATG5, ATG7 and/or ATG12) approaches for autophagy
suppression. This is connected with cytoprotective form of autophagy [68].
Autophagy has also been shown to protect against cellular stress induced by the anti-cancer
chemotherapeutic drugs (nonprotective autophagy) [68]. The cell is apparently carrying out
autophagy-mediated degradative functions but where autophagy inhibition does not lead to
perceptible alterations in drug or radiation sensitivity. Furthermore, because autophagy is
frequently upregulated in tumors in response to therapy, it may protect the tumors against
therapy-induced apoptosis [69]. Gewirtz reported that ionizing radiation could promote
autophagy in BC cells in cell culture but autophagy inhibition did not alter sensitivity to
radiation [68]. Furthermore, the group showed that chloroquine did not sensitize murine breast
tumor cells (4T1) to radiation in an immunocompetent animal model. Based on the results
obtained, it was impossible to determine whether radiation had promoted autophagy process
or the chloroquine actually effectively inhibited autophagy in the tumor-bearing animals.
Supposedly, that the lack of sensitization could be related to findings [5] that autophagy
inhibition interferes with the immune system's capability for recognition of the tumor
undergoing a stress response.
Such disclosures have led to several clinical trials involving the use of the autophagy flux
inhibitors as a combination therapy [70] to radiotherapy efficacy improvement in BC patients.
For example, to such inhibitors could be included hydroxychloroquine (HCQ). HCQ is a less
toxic version of CQ and the best autophagy inhibitor currently commercially available for
clinical trials [71]. Irradiated cancer cells can induce damage in neighboring un-irradiated cells
by intracellular gap-junction communication or signals released outside of the cells [72].
Huang et al. indicated that radiation-induced senescent MDA-MB- 231-2A cells are secreting
multiple cytokines and chemokines including CSF2 (colony stimulating factor; expressed in
the highest level), CXCL1(C-X-C motif ligand 1), IL-6 and IL-8 (interleukin 8) [73]. These factors
are involved in multiple functions during cancer progression. Autophagy inhibition in
MDAMB- 231-2A cells significantly decreased the release of CSF2 suggesting that autophagy
plays an important role in promoting the secretion of SASPs (senescence-associated secretory
phenotypes). In support of this notion, it has been reported that inhibition of autophagy delays
the secretion of several senescence-associated cytokines such as IL-6 and IL-8.
Cytotoxic autophagy is the next form of autophagy which should be taken under consideration
in the field of cancer treatment. Functionally, this form is associated with a reduction in the
number of viable cells and/or reduced clonogenic survival upon treatment [74]. For example,
Targeting the Autophagy Process in Breast Cancer Development and Treatment
http://dx.doi.org/10.5772/61181
71
Bristol et al. reported that vitamin D (or the vitamin D analog, EB 1089) can be combined with
radiation to promote a cytotoxic form of autophagy in breast tumor cell lines (MCF-7 and
ZR-75) [75]. Other research groups also showed that the generation of cytotoxic autophagy
may either independently lead to cells death or act as a precursor to apoptosis [76]. Gewirtz
identified an additional form of autophagy, termed cytostatic autophagy, in non–small cell
lung cancer cells (A549 and H460) which was induced in similar conditions to the ones
previously described with regards to breast tumor cells [74]. What distinguishes cytostatic
autophagy from the cytoprotective form is the failure to detect evidence of cell killing reported
in the breast tumor cells [74]. Both Gewirtz and Kroemer's group demonstrated cytoprotective
autophagy by radiation alone but the addition of vitamin D or EB 1089 converted cytoprotec‐
tive autophagy to cytostatic autophagy [74,77]. Kroemer’s group observed that the depletion
of essential autophagy-relevant gene products such as ATG5 and Beclin-1 increased the
sensitivity of human or mouse cancer cell lines (H460, A549 and CT26 cells) to irradiation both
in vitro (where autophagy inhibition increased radiation-induced cell death and decreased
clonogenic survival) and in vivo after transplantation of the cell lines into immunodeficient
BALB/c nude mice (where autophagy inhibition potentiated the tumor growth-inhibitory
effect of radiotherapy) [77].
As Ras⁄Raf⁄ERK pathway belongs to the most commonly deregulated pathways identified in
tumors and is currently the target of new antitumor strategies based on the inhibition of
upstream ERK regulators. Inhibiting ERK activity in combination therapy with classical
antitumor compounds might affect the efficiency of such compounds. For example, in MCF-7
human breast adenocarcinoma cell line such combined therapies with: doxorubicin [78],
tamoxifen [79], taxol [80] or Δ Raf1 [81] and, TNFα [82] were used. For example, tamoxifen,
the most commonly used antiestrogen, exerts its pharmacological action by binding to estrogen
receptor alpha (ERα) and blocking the growth promoting action of the estrogen in BC cells.
However, the development of antiestrogen resistance has become a major impediment in the
treatment of ER-positive BC. It was reported that autophagy plays a critical role in the
development of antiestrogen resistance and overexpression of Beclin-1 downregulated
estrogenic signaling and growth response [83].
5.1. Autophagic genes silencing
Some studies using gene silencing to receive therapeutic effect via cell death induction could
represent genetic therapeutic approaches. For example, the Bcl-2 protooncogene (preventing
cells from undergoing apoptosis) is overexpressed in half of all human malignancies and more
than 60% of BC. Bcl-2 overexpression not only leads to the resistance of cancer cells towards
chemotherapy, radiation and hormone therapy but also causes an aggressive tumor phenotype
in patients with a variety of cancers [23]. Recent findings suggested that silencing Bcl-2
expression (by siRNA) in MCF-7 cells led to significant autophagic, not apoptotic, cell death
[84]. It has been demonstrated that the knockdown of autophagy genes (e.g. ATG5 and
BECN1) significantly inhibited both autophagy and cell death induced by Bcl-2 siRNA after a
long-term treatment of up to seven days [84]. MCF-7 cells are known to be caspase 3-deficient
providing a higher threshold for the induction of apoptosis potentially rendering the auto‐
Cell Death - Autophagy, Apoptosis and Necrosis72
phagic cell death pathway more important. Furthermore, about 45-75% of tumor tissues from
BC patients do not have detectable caspase 3 expression [85]. Akar et al. reported that doxor‐
ubicin predominantly induced autophagy at low doses and apoptosis at high doses [84].
Furthermore, the combination of Bcl-2 siRNA treatment with a doxorubicin low dose enhanced
the autophagic response, tumor growth inhibition and cell death. It was the first evidence that
targeted silencing of Bcl-2 induction of autophagic cell death in BC cells so a new path for
further research on this type of alternative therapeutic strategies.
There are studies connecting autophagy genes profile with BC prognosis. For example, Gu et
al. separated BC patients into two groups according to the TP53 mutation status in their study
[86]. Then, detected the differential gene expression patterns of autophagy-related genes and
investigated the association of autophagy with BC prognosis. Using microarray analysis, they
identified a set of eight autophagy genes (BCL2, BIRC5, EIF4EBP1, ERO1L, FOS, GAPDH,
ITPR1 and VEGFA), which were significantly associated with overall survival in breast cancer.
This classifier could accurately predict the clinical outcome of BC independently of other
classical clinical factors such as age, tumor size, grade, status of lymph nodes, ER status, PR
status and ERBB2 status.
5.2. Pharmacological approach to the autophagic therapies
In pharmacological approach to the anti-tumor autophagic therapies, the aim is to activate or
inhibit autophagy. Many drugs and compounds that modulate autophagy are currently
receiving considerable attention [26,35]. For example, autophagy inducers such as rapamycin
(mTORC1 inhibitor) [26] and its analogs called rapalogs (such as Everolimus; RAD001) are
also often used as tools to study autophagy process [6]. Everolimus was shown to enhance the
sensitivity of tumors to radiation by induction of autophagy [6].
Also, natural products are considered as potential anti-cancer candidates being direct or
indirect sources of new chemotherapy adjuvants to enhance the efficacy of chemotherapy and/
or to ameliorate its side effects [87, 88].
The more challenging issue is the monitoring of autophagic activity in humans, in tissue and
blood samples. It seems to be more important to measure autophagic flux than autophagosome
number. However, measurements of autophagic flux in paraffin-embedded tissue samples
have been unsuccessful till now and even the detection of endogenous LC3-II (commonly used
marker for autophagosomes) is problematic in tissue sections [26]
6. Concluding remarks
There has been a tremendous amount of progress in our understanding of the role of autoph‐
agy in cancer. But still the molecular mechanisms underlying the regulation of autophagy and
the role of autophagy in cancer cells are not fully understood but are progressively revealed.
Overall, the data support a dynamic role of autophagy in cancer - both as a tumor suppressor
early in progression and later as a pro-tumorigenic process critical for tumor maintenance and
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therapeutic resistance. The specification of the autophagic cargo in tumors with increased
autophagy is important for understanding the changes in metabolism between normal and
malignant cells. Undoubtedly, progress in genomics, proteomics and metabolomics will be
helpful in this scope. Induction of autophagic cell death may be an ideal approach in resistant
cancers therapies. But most experiments regarding BC are carried out on cell lines in vitro.
Further, functional investigations of autophagy genes using BC cell lines and animal models
will increase our understanding of their roles in determining breast cancer prognosis and could
thereby provide clinical strategies for the treatment of breast cancer. The first clinical trials
where deliberate autophagy inhibition has been attempted in cancer patients are starting to be
reported [89-93]. For instance, autophagy inhibition by HCQ in combination with chemother‐
apy is currently being evaluated in multiple ongoing clinical trials in patients with solid tumors
but we should take into account that autophagic effect is context dependent. While tumor cell
susceptibility to autophagy may depend on tumor genotype and the therapeutic agents
utilized, data are very limited and it remains unclear whether such new strategies will be
clinically beneficial.
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